On the TRAIL to overcome BRAF-inhibitor resistance

Journal of Investigative Dermatology

Volumn 134, Issue 2, 2014, Pages 315-318

  Geserick, Peter ^a   Herlyn, Meenhard ^b   Leverkus, Martin ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE INHIBITOR; BIM PROTEIN; CASPASE 8; DABRAFENIB; FAS LIGAND; HYDROXYCHLOROQUINE; MITOGEN ACTIVATED PROTEIN KINASE; PROCASPASE 8; PROTEIN BCL 2; TRAMETINIB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VEMURAFENIB;

CANCER RESISTANCE; ENZYME PHOSPHORYLATION; METASTATIC MELANOMA; PRIORITY JOURNAL; REMISSION; REVIEW;

APOPTOSIS; HUMANS; MELANOMA; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDINES; SKIN NEOPLASMS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84892769070     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2013.348     Document Type: Note

References (16)

1. Berger A, Quast SA, Plötz M et al. (2014) RAF inhibition overcomes resistance to TRAIL-induced apoptosis in melanoma cells. J Invest Dermatol 134:430-40
2. Chapman PB, Hauschild A, Robert C et al. (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-16
3. Flaherty KT, Infante JR, Daud A et al. (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367:1694-703
4. Geserick P, Drewniok C, Hupe M et al. (2008) Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95Lmediated apoptosis. Oncogene 27:3211-20
5. Geserick P, Hupe M, Moulin M et al. (2009) Cellular IAPs inhibit a cryptic CD95-induced cell death by limiting RIP1 kinase recruitment. J Cell Biol 187:1037-54
6. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: The next generation. Cell 144:646-74
7. Haq R, Shoag J, Andreu-Perez P et al. (2013) Oncogenic BRAF regulates oxidative metabolism via PGC1alpha and MITF. Cancer Cell 23:302-15
8. Holzel M, Bovier A, Tuting T (2013) Plasticity of tumour and immune cells: A source of heterogeneity and a cause for therapy resistance? Nat Rev Cancer 13:365-76
9. Kim H, Tu HC, Ren D et al. (2009) Stepwise activation of BAX and BAK by tBID, BIM, and PUMA initiates mitochondrial apoptosis. Mol Cell 36:487-99
10. Knight DA, Ngiow SF, Li M et al. (2013) Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest 123: 1371-81
11. Morris EJ, Jha S, Restaino CR et al. (2013) Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov 3:742-50
12. Roesch A, Vultur A, Bogeski I et al. (2013) Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(-high) cells. Cancer Cell 23:811-25
13. Souers AJ, Leverson JD, Boghaert ER et al. (2013) ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19:202-8
14. Uzdensky AB, Demyanenko SV, Bibov MY (2013) Signal transduction in human cutaneous melanoma and target drugs. Curr Cancer Drug Targets; e-pub ahead of print 6 May 2013
15. Wolchok JD, Kluger H, Callahan MK et al. (2013) Nivolumab plus Ipilimumab in advanced melanoma. N Engl J Med 369:122-33
16. Xie X, White EP, Mehnert JM (2013) Coordinate autophagy and mTOR pathway inhibition enhances cell death in melanoma. PLoS ONE 8:e55096